Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

[Background] Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than on...

Descripción completa

Detalles Bibliográficos
Autores: Seymour, John F., Döhner, Hartmut, Butrym, Aleksandra, Wierzbowska, Agnieszka, Selleslag, Dominik, Jang, Jun Ho, Kumar, Rajat, Cavenagh, James, Schuh, Andre C., Candoni, Anna, Récher, Christian, Sandhu, Irwindeep, Bernal del Castillo, Teresa, Al-Ali, Haifa Kathrin, Falantes-González, José Francisco, Stone, Richard M., Minden, Mark D., Weaver, Jerry, Songer, Steve, Beach, C. L., Dombret, Hervé
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/180217
Acceso en línea:http://hdl.handle.net/10261/180217
Access Level:acceso abierto
Palabra clave:Azacitidine
Low-dose cytarabine
Acute myeloid leukemia
AML
Myelodysplasia-related changes
AML‐MRC
Induction chemotherapy
Response
Survival
Descripción
Sumario:[Background] Compared with World Health Organization-defined acute myeloid leukaemia (AML) not otherwise specified, patients with AML with myelodysplasia-related changes (AML-MRC) are generally older and more likely to have poor-risk cytogenetics, leading to poor response and prognosis. More than one-half of all older (≥65 years) patients in the phase 3 AZA-AML-001 trial had newly diagnosed AML-MRC.

Similares en LA Referencia